Abstract
Background: Disease recurrence in colorectal cancer constitutes a major cause of significant cancer-associated morbidity and mortality. MAP17 is a small protein, and its overexpression in malignant tumors has been correlated with aggressive tumor phenotypes. The aim of the present study was to investigate the expression patterns of MAP17 in colorectal cancer specimens and to assess its clinical significance. Patients and Methods: Surgical specimens of 111 patients with primary resectable colorectal cancer constituted the study population. Expression of MAP17 was assessed by immunohistochemistry, and the results were correlated with clinical and survival data. Results: MAP17 was expressed in cancer cells and endothelial cells of tumor blood vessels. Expression of MAP17 more than 10% was correlated with advanced disease stage (p < 0.001), higher T classification (p = 0.007), the presence of lymph node metastasis (p < 0.001), vascular (p = 0.013) and perineural invasion (p = 0.012). Patients exhibiting MAP17 expression of more than 30% in cancer cells compared to those expressing MAP17 less than 10% demonstrated a significantly worse 3-year progression-free survival (35.2 vs. 91%, p < 0.001) and 5-year overall survival (40.8 vs. 91%, p < 0.001). Cox regression analysis confirmed MAP17 expression of more than 30% as a prognostic marker of progression free survival (HR 0.136, 95% CI = 0.056–0.329, p < 0.001) and overall survival (HR 0.144 [95% CI) = 0.049–0.419, p < 0.001) independent of other clinicopathological characteristics. Statistically significantly worse 3-year progression-free survival and 5-year overall survival was demonstrated in the subgroup analysis of patients with early stage cancer only and high expression of MAP17. Conclusions: High MAP17 expression in patients with colorectal cancer is a significant risk factor for cancer-associated morbidity and mortality already in early stage disease.
References
1.
Siegel
RL
, Miller
KD
, Jemal
A
. Cancer statistics, 2016
. CA Cancer J Clin
. 20202020 Jan
;66
(1
):7
–30
. .2.
Brenner
H
, Kloor
M
, Pox
CP
. Colorectal cancer
. Lancet
. 2014 Apr 26
;383
(9927
):1490
–502
. 3.
Seyfried
TN
, Huysentruyt
LC
. On the origin of cancer metastasis
. Crit Rev Oncog
. 2013
;18
(1–2
):43
–73
. 4.
Boland
CR
, Goel
A
. Prognostic Subgroups among Patients with Stage II Colon Cancer
. N Engl J Med
. 2016 Jan 21
;374
(3
):277
–8
. 5.
Guyot
F
, Faivre
J
, Manfredi
S
, Meny
B
, Bonithon-Kopp
C
, Bouvier
AM
. Time trends in the treatment and survival of recurrences from colorectal cancer
. Ann Oncol
. 2005 May
;16
(5
):756
–61
. 6.
van Gestel
YR
, de Hingh
IH
, van Herk-Sukel
MP
, van Erning
FN
, Beerepoot
LV
, Wijsman
JH
, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer
. Cancer Epidemiol
. 2014 Aug
;38
(4
):448
–54
. 7.
Lugli
A
, Iezzi
G
, Hostettler
I
, Muraro
MG
, Mele
V
, Tornillo
L
, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
. Br J Cancer
. 2010 Jul 27
;103
(3
):382
–90
. 8.
Ailles
LE
, Weissman
IL
. Cancer stem cells in solid tumors
. Curr Opin Biotechnol
. 2007 Oct
;18
(5
):460
–6
. 9.
Polyak
K
, Weinberg
RA
. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
. Nat Rev Cancer
. 2009 Apr
;9
(4
):265
–73
. 10.
Grimshaw
MJ
, Cooper
L
, Papazisis
K
, Coleman
JA
, Bohnenkamp
HR
, Chiapero-Stanke
L
, et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells
. Breast Cancer Res
. 2008
;10
(3
):R52
. 11.
Marotta
LL
, Polyak
K
. Cancer stem cells: a model in the making
. Curr Opin Genet Dev
. 2009 Feb
;19
(1
):44
–50
. 12.
Rosen
JM
, Jordan
CT
. The increasing complexity of the cancer stem cell paradigm
. Science
. 2009 Jun 26
;324
(5935
):1670
–3
. 13.
Shackleton
M
, Quintana
E
, Fearon
ER
, Morrison
SJ
. Heterogeneity in cancer: cancer stem cells versus clonal evolution
. Cell
. 2009 Sep 4
;138
(5
):822
–9
. 14.
Shafee
N
, Smith
CR
, Wei
S
, Kim
Y
, Mills
GB
, Hortobagyi
GN
, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors
. Cancer Res
. 2008 May 1
;68
(9
):3243
–50
. 15.
To
K
, Fotovati
A
, Reipas
KM
, Law
JH
, Hu
K
, Wang
J
, et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance
. Cancer Res
. 2010 Apr 1
;70
(7
):2840
–51
. 16.
Hu
L
, McArthur
C
, Jaffe
RB
. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
. Br J Cancer
. 2010 Apr 13
;102
(8
):1276
–83
. 17.
Zhao
J
. Cancer stem cells and chemoresistance: The smartest survives the raid
. Pharmacol Ther
. 2016 Apr
;160
:145
–58
. 18.
Cammareri
P
, Scopelliti
A
, Todaro
M
, Eterno
V
, Francescangeli
F
, Moyer
MP
, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells
. Cancer Res
. 2010 Jun 1
;70
(11
):4655
–65
. 19.
Fang
DD
, Kim
YJ
, Lee
CN
, Aggarwal
S
, McKinnon
K
, Mesmer
D
, et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery
. Br J Cancer
. 2010 Apr 13
;102
(8
):1265
–75
. 20.
Ong
CW
, Kim
LG
, Kong
HH
, Low
LY
, Iacopetta
B
, Soong
R
, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer
. Mod Pathol
. 2010 Mar
;23
(3
):450
–7
. 21.
Dylla
SJ
, Beviglia
L
, Park
IK
, Chartier
C
, Raval
J
, Ngan
L
, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy
. PLoS One
. 2008 Jun 18
;3
(6
):e2428
. 22.
Guijarro
MV
, Link
W
, Rosado
A
, Leal
JF
, Carnero
A
. MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation
. Carcinogenesis
. 2007 Dec
;28
(12
):2443
–50
. 23.
Jaeger
C
, Schaefer
BM
, Wallich
R
, Kramer
MD
. The membrane-associated protein pKe#192/MAP17 in human keratinocytes
. J Invest Dermatol
. 2000 Sep
;115
(3
):375
–80
. 24.
Lanaspa
MA
, Giral
H
, Breusegem
SY
, Halaihel
N
, Baile
G
, Catalán
J
, et al. Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi
. Am J Physiol Renal Physiol
. 2007 Jan
;292
(1
):F230
–42
. 25.
Perez
M
, Praena-Fernandez
JM
, Felipe-Abrio
B
, Lopez-Garcia
MA
, Lucena-Cacace
A
, Garcia
A
, et al. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival
. PLoS One
. 2013
;8
(2
):e56169
. 26.
Guijarro
MV
, Vergel
M
, Marin
JJ
, Muñoz-Galván
S
, Ferrer
I
, Ramon y Cajal
S
, et al. p38α limits the contribution of MAP17 to cancer progression in breast tumors
. Oncogene
. 2012 Oct 11
;31
(41
):4447
–59
. 27.
Di Maro
G
, Orlandella
FM
, Bencivenga
TC
, Salerno
P
, Ugolini
C
, Basolo
F
, et al. Identification of targets of Twist1 transcription factor in thyroid cancer cells
. J Clin Endocrinol Metab
. 2014 Sep
;99
(9
):E1617
–26
. 28.
Inoue
J
, Otsuki
T
, Hirasawa
A
, Imoto
I
, Matsuo
Y
, Shimizu
S
, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma
. Am J Pathol
. 2004 Jul
;165
(1
):71
–81
. 29.
McShane
LM
, Altman
DG
, Sauerbrei
W
, Taube
SE
, Gion
M
, Clark
GM
. REporting recommendations for tumor MARKer prognostic studies (REMARK)
. Nat Clin Pract Urol
. 2005 Aug
;2
(8
):416
–22
30.
Rivero
M
, Peinado-Serrano
J
, Muñoz-Galvan
S
, Espinosa-Sánchez
A
, Suarez-Martinez
E
, Felipe-Abrio
B
, et al. MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy
. Oncotarget
. 2018 Aug 31
;9
(68
):32958
–71
. 31.
Guijarro
MV
, Leal
JF
, Fominaya
J
, Blanco-Aparicio
C
, Alonso
S
, Lleonart
M
, et al. MAP17 overexpression is a common characteristic of carcinomas
. Carcinogenesis
. 2007 Aug
;28
(8
):1646
–52
. 32.
Rodriguez-Rodero
S
, Fernandez
AF
, Fernandez-Morera
JL
, Castro-Santos
P
, Bayon
GF
, Ferrero
C
, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes
. J Clin Endocrinol Metab
. 2013 Jul
;98
(7
):2811
–21
33.
Chen
X
, Liao
Y
, Yu
Y
, Zhu
P
, Li
J
, Qin
L
, et al. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma
. Oncotarget
. 2017 Nov 3
;8
(54
):92589
–603
. 34.
Perez
M
, Peinado-Serrano
J
, Garcia-Heredia
JM
, Felipe-Abrio
I
, Tous
C
, Ferrer
I
, et al. Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)
. Oncotarget
. 2016 Oct 11
;7
(41
):67033
–46
. 35.
Carnero
A
. MAP17 and the double-edged sword of ROS
. Biochim Biophys Acta
. 2012 Aug
;1826
(1
):44
–52
. 36.
Garcia-Heredia
JM
, Lucena-Cacace
A
, Verdugo-Sivianes
EM
, Pérez
M
, Carnero
A
. The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB
. Clin Cancer Res
. 2017 Jul 15
;23
(14
):3871
–83
. 37.
Zhang
Y
, Li
B
, Ji
ZZ
, Zheng
PS
. Notch1 regulates the growth of human colon cancers
. Cancer
. 2010 Nov 15
;116
(22
):5207
–18
. 38.
Kandoth
C
, McLellan
MD
, Vandin
F
, Ye
K
, Niu
B
, Lu
C
, et al. Mutational landscape and significance across 12 major cancer types
. Nature
. 2013 Oct 17
;502
(7471
):333
–9
. 39.
Ranganathan
P
, Weaver
KL
, Capobianco
AJ
. Notch signalling in solid tumours: a little bit of everything but not all the time
. Nat Rev Cancer
. 2011 May
;11
(5
):338
–51
. 40.
Garcia-Heredia
JM
, Carnero
A
. The cargo protein MAP17 [PDZK1IP1] regulates the immune microenvironment
. Oncotarget
. 2017 Nov 17
;8
(58
):98580
–97
41.
Marchesi
M
, Andersson
E
, Villabona
L
, Seliger
B
, Lundqvist
A
, Kiessling
R
, et al. HLA-dependent tumour development: a role for tumour associate macrophages?
J Transl Med
. 2013 Oct 6
;11
:247
. 42.
Jones
DC
, Kosmoliaptsis
V
, Apps
R
, Lapaque
N
, Smith
I
, Kono
A
, et al. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding
. J Immunol
. 2011 Mar 1
;186
(5
):2990
–7
. 43.
Colonna
M
, Borsellino
G
, Falco
M
, Ferrara
GB
, Strominger
JL
. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells
. Proc Natl Acad Sci USA
. 1993 Dec 15
;90
(24
):12000
–4
. 44.
Anfossi
N
, Doisne
JM
, Peyrat
MA
, Ugolini
S
, Bonnaud
O
, Bossy
D
, et al. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells
. J Immunol
. 2004 Dec 15
;173
(12
):7223
–9
. 45.
Munoz-Galvan
S
, Gutierrez
G
, Perez
M
, Carnero
A
. MAP17 [PDZKIP1] expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFkappaB activation in breast cancer
. Mol Cancer Ther
. 2015 Jun
;14
(6
):1454
–65
46.
de Miguel-Luken
MJ
, Chaves-Conde
M
, de Miguel-Luken
V
, Muñoz-Galván
S
, López-Guerra
JL
, Mateos
JC
, et al. MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer
. Oncotarget
. 2015 May 20
;6
(14
):12625
–36
. 47.
de Miguel-Luken
MJ
, Chaves-Conde
M
, Carnero
A
. A genetic view of laryngeal cancer heterogeneity
. Cell Cycle
. 2016 May 2
;15
(9
):1202
–12
. 48.
Ferrer
I
, Quintanal-Villalonga
Á
, Molina-Pinelo
S
, Garcia-Heredia
JM
, Perez
M
, Suárez
R
, et al. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
. J Exp Clin Cancer Res
. 2018 Aug 17
;37
(1
):195
. 49.
Marshall
JL
. Risk assessment in Stage II colorectal cancer
. Oncology (Williston Park, NY)
. 2010 Jan
;24
(1 Suppl 1
):9
–13
50.
Benson
AB
3rd, Schrag
D
, Somerfield
MR
, Cohen
AM
, Figueredo
AT
, Flynn
PJ
, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
. J Clin Oncol
. 2004 Aug 15
;22
(16
):3408
–19
. © 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
